

References

Passion Flower

- Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op
Phytother, 1997. **1**
- Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994. **3**
- Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals.
London, UK: The Pharmaceutical Press, 1996. **4**
- The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co.,
1999. **6**
- Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine.
Terry C. Telger, transl. 3rd ed. Berlin, GER: Springer, 1998. **7**
- Martindale W. Martindale the Extra Pharmacopoeia. Pharmaceutical Press, 1999. **9**
- Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and
Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996. **11**
- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical
Economics Company, Inc., 1998. **18**
- Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press,
1999. **515**
- Akhondzadeh S, Kashani L, Mobaseri M, et al. Passionflower in the treatment of opiates
withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 2001;26:369-73. [View
abstract.](#) **2303**
- Salgueiro JB, Ardenghi P, Dias M, et al. Anxiolytic natural and synthetic flavonoid ligands of the
central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem
Behav 1997;58:887-91. [View abstract.](#) **4001**
- Rommelspacher H, May T, Salewski B. (1-methyl-beta-carboline) is a natural inhibitor of
monoamine oxidase type A in rats. Eur J Pharmacol 1994;252:51-9.. [View abstract.](#) **4002**
- Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of
outpatients with adjustment disorder with anxious mood: controlled study vs placebo. Fundam
Clin Pharmacol 1997;11:127-32. [View abstract.](#) **6250**
- Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol
2000;38:63-6. [View abstract.](#) **6251**
- Akhondzadeh S, Naghavi HR, Shayeganpour A, et al. Passionflower in the treatment of
generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm
Ther 2001;26:363-7. [View abstract.](#) **8007**
- Medina JH, Paladini AC, Wolfman C, et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring
ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol
1990;40:2227-31. [View abstract.](#) **8167**
- 8811**

- Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of *Passiflora incarnata*. *Fitoterapia* 2001;72:922-6.. [View abstract](#). **9558**
- Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of *Passiflora incarnata* Linneaus. *J Ethnopharmacol* 2001;78:165-70.. [View abstract](#). **11020**
- Farnsworth N, Bingel A, Cordell G, et al. Potential value of plants as sources of new antifertility agents I. *J Pharm Sci* 1975;64:535-98. [View abstract](#). **15339**
- Aoyagi N, Kimura R, Murata T. Studies on *passiflora incarnata* dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol. *Chem Pharm Bull* 1974;22:1008-13. [View abstract](#). **15340**
- Gralla EJ, Stebbins RB, Coleman GL, Delahunt CS. Toxicity studies with ethyl maltol. *Toxicol Appl Pharmacol* 1969;15:604-13. [View abstract](#). **15391**
- Mori A, Hasegawa K, Murasaki M, et al. Clinical evaluation of Passiflamin (*passiflora* extract) on neurosis - multicenter double blind study in comparison with mexazolam. *Rinsho Hyoka (Clinical Evaluation)* 1993;21:383-440. **15392**
- Miyasaka LS, Atallah AN, Soares BG. *Passiflora* for anxiety disorder. *Cochrane Database Syst Rev* 2007;(1):CD004518. [View abstract](#). **17374**
- Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of *Passiflora incarnata* (*Passionflower*) herbal tea on subjective sleep quality. *Phytother Res* 2011;25:1153-9. [View abstract](#). **19201**
- Von Eiff M, Brunner H, Haegeli A, et al. Hawthorn / passion flower extract and improvement in physical exercise capacity of patients with dyspnoea Class II of the NYHA functional classifications. *Acta Therapeutica* 1994;20:47-66. **19235**
- Speroni E., Minghetti A. Neuropharmacological activity of extracts from *Passiflora incarnata*. *Planta Med.* 1988;54:488-91. [View abstract](#). **19236**
- Capasso A., Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of *Kava kava* and *Passiflora* extracts combination. *Phytomedicine.* 2005;12:39-45. [View abstract](#). **19429**
- Carrasco MC, Vallejo JR, Pardo-de-Santayana M, et al. Interactions of *Valeriana officinalis* L. and *Passiflora incarnata* L. in a patient treated with lorazepam. *Phytother Res.* 2009 Dec;23:1795-6. [View abstract](#). **42950**
- Brown, E., Hurd, N. S., McCall, S., and Ceremuga, T. E. Evaluation of the anxiolytic effects of chrysin, a *Passiflora incarnata* extract, in the laboratory rat. *AANA.J* 2007;75(5):333-337. [View abstract](#). **42955**
- Wolfman, C., Viola, H., Paladini, A., Dajas, F., and Medina, J. H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from *Passiflora coerulea*. *Pharmacol Biochem Behav* 1994;47(1):1-4. [View abstract](#). **68296**
- Dhawan, K., Kumar, S., and Sharma, A. Comparative biological activity study on *Passiflora incarnata* and *P. edulis*. *Fitoterapia* 2001;72(6):698-702. [View abstract](#). **68298**
- Nassiri-Asl, M., Shariati-Rad, S., and Zamansoltani, F. Anticonvulsant effects of aerial parts of *Passiflora incarnata* extract in mice: involvement of benzodiazepine and opioid receptors. *BMC.Complement Altern Med* 2007;7:26. [View abstract](#). **68299**

- Gerhard, U., Hobi, V., Kocher, R., and Konig, C. [Acute sedating effect of a herbal tranquilizer compared to that of bromazepam]. *Schweiz.Rundsch.Med.Prax.* 12-27-1991;80(52):1481-1486. [View abstract.](#) **68304**
- Rickels, K. and Hesbacher, P. T. Over-the-counter daytime sedatives. A controlled study. *JAMA* 1-1-1973;223(1):29-33. [View abstract.](#) **68307**
- Yaniv, R., Segal, E., Trau, H., Auslander, S., and Perel, A. Natural premedication for mast cell proliferative disorders. *J Ethnopharmacol.* 1995;46(1):71-72. [View abstract.](#) **68308**
- Smith, G. W., Chalmers, T. M., and Nuki, G. Vasculitis associated with herbal preparation containing *Passiflora* extract. *Br J Rheumatol.* 1993;32(1):87-88. [View abstract.](#) **68309**
- Soulimani, R., Younos, C., Jarmouni, S., Boust, D., Misslin, R., and Mortier, F. Behavioural effects of *Passiflora incarnata* L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. *J Ethnopharmacol.* 1997;57(1):11-20. [View abstract.](#) **68310**
- Von Eiff M, Brunner H, Haegeli A, and et al. Hawthorn / passion flower extract and improvement in physical exercise capacity of patients with dyspnoea Class II of the NYHA functional classifications. *Acta Therapeutica* 1994;20:47-66. **88193**
- Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. *Indian J Pharmacol* 2013;45(1):34-9. [View abstract.](#) **88194**
- Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. *Passiflora incarnata* Linnaeus as an anxiolytic before spinal anesthesia. *J Anesth* 2012;26(1):39-44. [View abstract.](#) **88195**
- Kaviani N, Tavakoli M, Tabanmehr M, Havaei R. The efficacy of *Passiflora incarnata* Linnaeus in reducing dental anxiety in patients undergoing periodontal treatment. *J Dent (Shiraz)* 2013;14(2):68-72. [View abstract.](#) **88196**
- Movafegh A, Alizadeh R, Hajimohamadi F, Esfehni F, Nejatfar M. Preoperative oral *Passiflora incarnata* reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. *Anesth Analg* 2008;106:1728-32. [View abstract.](#) **88197**
- Akhondzadeh S, Mohammadi MR, Momeni F. *Passiflora incarnata* in the treatment of attention-deficit hyperactivity disorder in children and adolescents. *Therapy* 2005;2(4):609-14. **88198**
- Anseau M, Seidel L, Crosset A, Dierckxsens Y, Albert A. A dry extract of *Passiflora incarnata* L. (*Sedanxio*) as first intention treatment of patients consulting for anxiety problems in general practice. *Acta Psychiatrica Belgica* 2012;112(3):5-11. **88199**
- Miroddi M, Calapai G, Navarra M, et al. *Passiflora incarnata* L: ethnopharmacology, clinical application, safety and evaluation of clinical trials. *J Ethnopharmacol* 2013;150:791-804. [View abstract.](#) **88200**
- Patel SS, Mohamed Saleem TS, Ravi V, et al. *Passiflora incarnata* Linn: a phytopharmacological review. *Int J Green Pharmacy* 2009;Oct-Dec:277-80. **91203**
- Code of Federal Regulations Title 21, Chapter 1, Subchapter B, section 172.510: Natural flavoring substances and natural substances used in conjunction with flavors. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=172.510 (accessed 02/22/16). **91204**
- Appel K, Rose T, Fiebich B, et al. Modulation of the gamma-aminobutyric acid (GABA) system by *Passiflora incarnata* L. *Phytother Res* 2011;25:838-43. [View abstract.](#)

Grundmann O, Wang J, McGregor GP, Butterweck V. Anxiolytic activity of a phytochemically characterized *Passiflora incarnata* extract is mediated via the GABAergic system. *Planta Medica* 2008;74:1769-73. [View abstract](#).